Handel Calcimedica Inc - CALC CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.4586 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 0.001 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 5.4929 |
Åben* | 5.4688 |
1-Års Ændring* | 317.47% |
Dagens Spænd* | 5.4688 - 5.7853 |
52-Ugers Spænd | 4.88-20.30 |
Gennemsnitlig Volumen (10 dage) | 22.09K |
Gennemsnitlig Volumen (3 måneder) | 103.52K |
Market Cap | 8.89M |
P/E-forhold | -100.00K |
Udestående aktier | 5.52M |
Omsætning | N/A |
EPS | -23.21 |
Dividend (Udbytte %) | N/A |
Beta | -100.00K |
Næste indtjeningsopgørelse | May 8, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 5.5507 | 0.0832 | 1.52% | 5.4675 | 5.7853 | 5.4675 |
Mar 23, 2023 | 5.4929 | 0.1525 | 2.86% | 5.3404 | 5.8023 | 5.3404 |
Mar 22, 2023 | 5.5768 | 0.2301 | 4.30% | 5.3467 | 6.5507 | 5.0805 |
Mar 21, 2023 | 6.0468 | 1.2311 | 25.56% | 4.8157 | 6.1436 | 4.7284 |
Mar 20, 2023 | 5.3451 | -0.6469 | -10.80% | 5.9920 | 5.9920 | 5.0602 |
Mar 17, 2023 | 0.4280 | -0.0478 | -10.05% | 0.4758 | 0.4763 | 0.4273 |
Mar 16, 2023 | 0.4761 | -0.0195 | -3.93% | 0.4956 | 0.4958 | 0.4580 |
Mar 15, 2023 | 0.4937 | 0.0277 | 5.94% | 0.4660 | 0.4969 | 0.4660 |
Mar 14, 2023 | 0.4762 | -0.0145 | -2.95% | 0.4907 | 0.4957 | 0.4737 |
Mar 13, 2023 | 0.4960 | -0.0093 | -1.84% | 0.5053 | 0.5151 | 0.4859 |
Mar 10, 2023 | 0.5041 | 0.0008 | 0.16% | 0.5033 | 0.5120 | 0.4857 |
Mar 9, 2023 | 0.5346 | -0.0034 | -0.63% | 0.5380 | 0.5637 | 0.5164 |
Mar 8, 2023 | 0.5638 | 0.0408 | 7.80% | 0.5230 | 0.5647 | 0.5230 |
Mar 7, 2023 | 0.5637 | 0.0395 | 7.54% | 0.5242 | 0.5823 | 0.5242 |
Mar 6, 2023 | 0.5556 | -0.0273 | -4.68% | 0.5829 | 0.5829 | 0.5537 |
Mar 3, 2023 | 0.5476 | 0.0429 | 8.50% | 0.5047 | 0.5588 | 0.5047 |
Mar 2, 2023 | 0.5345 | 0.0292 | 5.78% | 0.5053 | 0.5347 | 0.5053 |
Mar 1, 2023 | 0.5390 | 0.0045 | 0.84% | 0.5345 | 0.5832 | 0.5339 |
Feb 28, 2023 | 0.5285 | -0.0056 | -1.05% | 0.5341 | 0.5347 | 0.5179 |
Feb 27, 2023 | 0.5536 | -0.0004 | -0.07% | 0.5540 | 0.5543 | 0.5343 |
Calcimedica Inc Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Total omsætning | 0 | 0 | 0 | 0 |
Totale Driftsudgifter | 35.947 | 29.832 | 37.502 | 28.57 |
Salgs/Generelle/Admin. Udgifter, Total | 17.044 | 8.87 | 6.922 | 5.599 |
Forskning & Udvikling | 18.903 | 20.962 | 30.58 | 22.971 |
Driftsindtægter | -35.947 | -29.832 | -37.502 | -28.57 |
Renteindkomst (Udgift), Netto Ikke-Drift | 0.126 | 0.143 | 0.393 | 0.192 |
Andre, Netto | 0 | 2.158 | 0.072 | 0 |
Netto Indkomst Før Skat | -35.821 | -27.531 | -37.037 | -28.378 |
Netto Indkomst Efter Skat | -35.821 | -27.531 | -37.037 | -28.378 |
Netto Indkomst Før Ekstra Ting | -35.821 | -27.531 | -37.037 | -28.378 |
Netto Indkomst | -35.821 | -27.531 | -37.037 | -28.378 |
Total Adjustments to Net Income | 0 | -7.189 | -7.055 | -4.317 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -35.821 | -34.72 | -44.092 | -32.695 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -35.821 | -34.72 | -44.092 | -32.695 |
Fortyndet Netto Indkomst | -35.821 | -34.72 | -44.092 | -32.695 |
Fortyndet Vægtet Gennemsnit Aktier | 21.1993 | 21.044 | 19.1556 | 19.1556 |
Fortyndet EPS Uden Ekstraordinære Ting | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Fortyndet Normaliseret EPS | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total omsætning | 0 | 0 | 0 | 0 | 0 |
Totale Driftsudgifter | 10.184 | 8.701 | 8.017 | 7.741 | 11.488 |
Salgs/Generelle/Admin. Udgifter, Total | 4.127 | 4.433 | 3.996 | 3.575 | 5.04 |
Forskning & Udvikling | 6.057 | 4.268 | 4.021 | 4.166 | 6.448 |
Driftsindtægter | -10.184 | -8.701 | -8.017 | -7.741 | -11.488 |
Renteindkomst (Udgift), Netto Ikke-Drift | 0.035 | 0.026 | 0.028 | 0.033 | 0.039 |
Andre, Netto | 0 | 0 | 0 | 0 | |
Netto Indkomst Før Skat | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Netto Indkomst Efter Skat | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Netto Indkomst Før Ekstra Ting | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Netto Indkomst | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Fortyndet Netto Indkomst | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
Fortyndet Vægtet Gennemsnit Aktier | 21.3578 | 21.3376 | 21.2875 | 21.1487 | 21.0204 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Totale Nuværende Aktiver | 67.078 | 99.24 | 36.271 | 13.445 |
Likvider og Kortsigtede Investeringer | 63.67 | 95.033 | 35.956 | 12.834 |
Likvider & Lignende | 13.364 | 33.418 | 15.87 | 12.834 |
Kortsigtede Investeringer | 50.306 | 61.615 | 20.086 | 0 |
Prepaid Expenses | 2.034 | 4.207 | 0.315 | 0.611 |
Total Assets | 69.088 | 101.794 | 40.66 | 17.813 |
Property/Plant/Equipment, Total - Net | 1.981 | 1.946 | 1.975 | 1.515 |
Property/Plant/Equipment, Total - Gross | 3.634 | 3.08 | 2.714 | 1.958 |
Accumulated Depreciation, Total | -1.653 | -1.134 | -0.739 | -0.443 |
Other Long Term Assets, Total | 0.029 | 0.608 | 2.414 | 2.853 |
Total Current Liabilities | 4.057 | 6.997 | 12.251 | 5.794 |
Accounts Payable | 0.527 | 2.513 | 4.636 | 2.523 |
Accrued Expenses | 2.582 | 3.658 | 4.377 | 2.924 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.948 | 0.826 | 3.238 | 0.347 |
Total Liabilities | 4.065 | 7.008 | 12.251 | 5.794 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Total Equity | 65.023 | 94.786 | 28.409 | 12.019 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 131.363 | 78.811 |
Common Stock | 0.002 | 0.002 | 0 | 0 |
Additional Paid-In Capital | 234.225 | 228.155 | 2.879 | 2.007 |
Retained Earnings (Accumulated Deficit) | -169.188 | -133.367 | -105.836 | -68.799 |
Unrealized Gain (Loss) | -0.016 | -0.004 | 0.003 | 0 |
Total Liabilities & Shareholders’ Equity | 69.088 | 101.794 | 40.66 | 17.813 |
Total Common Shares Outstanding | 21.3578 | 20.9793 | 19.1556 | 19.1556 |
Other Liabilities, Total | 0.008 | 0.011 | ||
Total Preferred Shares Outstanding | 0 | |||
Totale Tilgodehavender, Netto | 0.021 | |||
Other Current Assets, Total | 1.353 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 58.222 | 67.078 | 74.496 | 76.051 | 88.821 |
Likvider og Kortsigtede Investeringer | 55.28 | 63.67 | 72.554 | 73.586 | 85.688 |
Likvider & Lignende | 8.36 | 13.364 | 11.452 | 7.864 | 10.589 |
Kortsigtede Investeringer | 46.92 | 50.306 | 61.102 | 65.722 | 75.099 |
Prepaid Expenses | 2.942 | 3.408 | 1.942 | 2.465 | 3.133 |
Total Assets | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
Property/Plant/Equipment, Total - Net | 2.335 | 1.981 | 2.113 | 2.006 | 2.002 |
Other Long Term Assets, Total | 0.029 | 0.029 | 0.029 | 0.136 | 0.029 |
Total Current Liabilities | 4.228 | 4.057 | 4.49 | 4.141 | 6.278 |
Accounts Payable | 0.541 | 0.527 | 2.066 | 2.101 | 1.956 |
Accrued Expenses | 2.216 | 2.582 | 1.729 | 1.543 | 3.378 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.471 | 0.948 | 0.695 | 0.497 | 0.944 |
Total Liabilities | 4.33 | 4.065 | 4.502 | 4.154 | 6.29 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.102 | 0.008 | 0.012 | 0.013 | 0.012 |
Total Equity | 56.256 | 65.023 | 72.136 | 78.667 | 84.562 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 235.767 | 234.225 | 232.641 | 231.183 | 229.376 |
Retained Earnings (Accumulated Deficit) | -179.337 | -169.188 | -160.513 | -152.524 | -144.816 |
Unrealized Gain (Loss) | -0.176 | -0.016 | 0.006 | 0.006 | 0 |
Total Liabilities & Shareholders’ Equity | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
Total Common Shares Outstanding | 21.3578 | 21.3578 | 21.3166 | 21.2847 | 21.0559 |
Long Term Investments | 4.628 | ||||
Preferred Stock - Non Redeemable, Net | 0 | 0 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Netto indkomst/Startlinje | -35.821 | -27.531 | -37.037 | -28.378 |
Likvider Fra Driftsaktiviteter | -31.5 | -32.064 | -31.215 | -28.216 |
Likvider Fra Driftsaktiviteter | 0.519 | 0.395 | 0.303 | 0.175 |
Ikke-Likvide Ting | 5.433 | -0.369 | 0.598 | 0.366 |
Ændringer i Driftskapital | -1.631 | -4.559 | 4.921 | -0.379 |
Likvider fra Investeringsaktiviteter | 10.751 | -42.56 | -20.62 | -1.461 |
Kapitaludgifter | -0.488 | -1.023 | -0.605 | -1.461 |
Andre Investerings-Cash-Flow-Ting, Total | 11.239 | -41.537 | -20.015 | 0 |
Likvider fra Financieringsaktiviteter | 0.695 | 92.172 | 54.871 | 42.019 |
Financiering af Cash-Flow-Ting | 0 | -4.16 | -0.045 | 0 |
Udstedelse (Pensionering) af Aktier, Netto | 0.695 | 96.332 | 54.916 | 42.019 |
Netto Ændring i Likviditet | -20.054 | 17.548 | 3.036 | 12.342 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -10.149 | -35.821 | -27.146 | -19.157 | -11.449 |
Cash From Operating Activities | -6.524 | -31.5 | -22.545 | -17.045 | -9.264 |
Cash From Operating Activities | 0.122 | 0.519 | 0.383 | 0.247 | 0.118 |
Non-Cash Items | 3.81 | 5.433 | 3.946 | 2.508 | 1.169 |
Changes in Working Capital | -0.307 | -1.631 | 0.272 | -0.643 | 0.898 |
Cash From Investing Activities | 1.52 | 10.751 | -0.035 | -9.096 | -13.657 |
Capital Expenditures | 0 | -0.488 | -0.484 | -0.304 | -0.136 |
Other Investing Cash Flow Items, Total | 1.52 | 11.239 | 0.449 | -8.792 | -13.521 |
Cash From Financing Activities | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
Net Change in Cash | -5.004 | -20.054 | -21.966 | -25.554 | -22.829 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Deerfield Management Company, L.P. | Hedge Fund | 6.8373 | 377265 | 0 | 2022-12-31 | MED |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 5.3895 | 297380 | -2 | 2023-03-22 | LOW |
BML Capital Management LLC | Investment Advisor | 1.6 | 88282 | 0 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.5436 | 29995 | 13 | 2022-12-31 | LOW |
Guerard (Frederic) | Individual Investor | 0.4451 | 24562 | 16153 | 2023-03-03 | HIGH |
CVF 2018, LLC | Corporation | 0.3531 | 19485 | -56817 | 2021-12-31 | |
First Manhattan Co. LLC | Investment Advisor | 0.3512 | 19381 | -1476 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.2019 | 11143 | -3178 | 2022-12-31 | HIGH |
Breuil (Robert S) | Individual Investor | 0.1861 | 10266 | 5360 | 2023-03-14 | HIGH |
Zamiri (Parisa) | Individual Investor | 0.1495 | 8247 | 5554 | 2023-03-03 | HIGH |
BNY Mellon Asset Management | Investment Advisor | 0.1297 | 7159 | -54 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.0857 | 4730 | -12 | 2022-12-31 | LOW |
Johnson & Johnson Innovation-JJDC, Inc. | Venture Capital | 0.0641 | 3539 | 0 | 2022-12-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.0581 | 3204 | -1313 | 2022-12-31 | MED |
Hatteras Venture Partners | Venture Capital | 0.0557 | 3076 | -111584 | 2021-12-31 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.0542 | 2993 | -1578 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0454 | 2505 | 0 | 2022-12-31 | LOW |
Advisor Group, Inc | Investment Advisor | 0.0246 | 1357 | 0 | 2022-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0208 | 1150 | 0 | 2022-12-31 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.0154 | 851 | 0 | 2022-12-31 | MED |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Graybug Vision, Inc. Company profile
Om Graybug Vision, Inc.
Graybug Vision, Inc. er en biofarmaceutisk virksomhed i den kliniske fase, der fokuserer på at udvikle transformative lægemidler til behandling af sygdomme i nethinden og synsnerven. Selskabets førende produktkandidat, GB-102, er en intravitreal injektion af en mikropartikeldepotformulering af sunitinib, en hæmmer af neovaskulær vækst og permeabilitet, som er årsager til nethindesygdomme. Virksomheden er ved at udvikle GB-102 som en intravitreal injektion én gang hver sjette måned til behandling af våd aldersrelateret makuladegeneration eller våd (AMD) og diabetisk makulaødem (DME). Virksomheden anvender også sine teknologier til at udvikle GB-103, en formulering af GB-102, der anvendes én gang om året, til behandling af diabetisk retinopati (DR), samt GB-401, en intravitrealt injicerbar depotformulering af et prodrug af et beta-adrenergt blokerende middel med et doseringsskema på én gang hver sjette måned eller længere til behandling af primær åbenvinklet glaukom (POAG).
Industry: | Bio Therapeutic Drugs |
505 Coast Boulevard South
Suite 307
LA JOLLA
CALIFORNIA 92037
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com